Previous 10 | Next 10 |
2023-12-13 12:02:48 ET More on Biogen, Eisai, etc. Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Eisai Co., Ltd. 2023 Q2 - Results - Earnings Call Presentation Merck Keytruda combo fails ...
2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...
2023-12-12 03:49:29 ET Summary Today, we take a deeper look at Denali Therapeutics, a biotech company focused on developing treatments for neurodegenerative and lysosomal storage diseases. Denali's developmental focus has drawn several collaboration partnerships from much larger d...
2023-12-09 13:52:00 ET One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the advice. Take, for instance, Aurora Cannabis (NASDAQ: ACB) ...
2023-12-07 15:13:39 ET More on Biogen Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Biogen's Uncertain Strategic Pivots Amidst MS Market Challenges Ionis says Angelman syndrome drug well ...
2023-12-06 13:16:08 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...
2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...
2023-11-29 18:23:20 ET More on Lexeo Therapeutics, Inc. Stocks To Watch: Spotlight On OPEC Meeting, Amazon AWS Event, Tesla's Cybertruck Reveal, And Box Office Drama Lexeo Therapeutics Proposes Terms For $126 Million IPO Lexeo Therapeutics Starts $100 Million U.S. IP...
2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...
News, Short Squeeze, Breakout and More Instantly...
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...